VANGUARD GROUP INC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 18 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$434,000
-63.1%
1,313,996
-19.6%
0.00%
Q2 2020$1,177,000
+120.8%
1,634,200
-0.3%
0.00%
Q1 2020$533,000
-53.7%
1,638,5550.0%0.00%
Q4 2019$1,150,000
+24.5%
1,638,555
+20.6%
0.00%
Q3 2019$924,000
-61.7%
1,358,655
-6.5%
0.00%
Q2 2019$2,413,000
-20.3%
1,453,160
+20.0%
0.00%
Q1 2019$3,027,000
+5.6%
1,210,663
+7.3%
0.00%
Q4 2018$2,866,000
-47.6%
1,128,525
+4.2%
0.00%
Q3 2018$5,467,000
+54.9%
1,082,6740.0%0.00%
Q2 2018$3,530,000
+5.0%
1,082,674
+16.5%
0.00%
Q1 2018$3,363,000
+386.0%
928,979
+172.3%
0.00%
Q4 2017$692,000
+66.3%
341,191
+39.5%
0.00%
Q3 2017$416,000
+15.9%
244,552
+80.8%
0.00%
Q2 2017$359,000
-46.7%
135,234
+38.9%
0.00%
Q1 2017$674,000
+318.6%
97,393
+35.7%
0.00%
Q4 2016$161,000
-3.0%
71,758
+0.6%
0.00%
Q3 2016$166,000
-14.9%
71,358
-4.9%
0.00%
Q2 2016$195,000
-9.7%
75,0000.0%0.00%
Q1 2016$216,000
-34.3%
75,000
-0.7%
0.00%
Q4 2015$329,000
-99.7%
75,550
-98.3%
0.00%
-100.0%
Q3 2015$131,473,000
+15778.4%
4,355,424
+5765.9%
0.01%
Q2 2015$828,00074,2500.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2017
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders